Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAspirus Arise Abecma Coverage & Prior Auth | OpenP…
    Ask Trek AI about this page
    CurrentAspirus ArisePOLICY 250

    Abecma (idecabtagene vicleucel) CAR‑T therapy coverage

    Customize your policy alerts

    Sign up for Aspirus Arise POLICY 250 alerts

    Get alerted when POLICY 250 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, coverage criteria, dosing, and exclusions for Abecma (idecabtagene vicleucel) for Aspirus Medicare Plans for treatment of relapsed/refractory multiple myeloma.

    Policy Summary
    PayerAspirus Arise
    PolicyAbecma (idecabtagene vicleucel) CAR‑T therapy coverage
    Policy CodePolicy POLICY 250
    Change TypeDose and prior-therapy threshold revisionsadded alternative prior-lines pathway
    Effective DateJul 1, 2021
    Last ReviewMar 25, 2025
    Next Review DateMar 25, 2025
    Key ActionObtain prior authorization with documentation that the adult patient meets the age, prior‑therapy, lymphodepletion plan, and no prior CAR‑T criteria to request a single dose.
    SourceLink
    POLICY UPDATE CHANGES

    Added patient has received at least three prior lines of therapy as a new option for approval.

    Revised Abecma dose from 'up to 460 x 10^6 CAR-positive T-cells' to 'up to 510 x 10^6 CAR-positive T-cells'.

    Revised required prior lines threshold from four or more to two or more lines of systemic therapy (with specified agents) as primary pathway to approval.

    Approval duration set to 6 months to allow preparation and administration of a single dose.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥18minimum patient age for approval
    2primary prior-lines requirement
    ≥3alternative prior-lines pathway
    300–510approved single-dose range
    6 monthsauthorization duration